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The Molecular Inversion Probe (MIP) assay has been previously applied to a large-scale human SNP detection. Here we describe
the PathogenMip Assay, a complete protocol for probe production and applied approaches to pathogen detection. We have
demonstrated the utility of this assay with an initial set of 24 probes targeting the most clinically relevant HPV genotypes
associated with cervical cancer progression. Probe construction was based on a novel, cost-effective, ligase-based protocol.
The assay was validated by performing pyrosequencing and Microarray chip detection in parallel experiments. HPV plasmids
were used to validate sensitivity and selectivity of the assay. In addition, 20 genomic DNA extracts from primary tumors were
genotyped with the PathogenMip Assay results and were in 100% agreement with conventional sequencing using an L1-based
HPV genotyping protocol. The PathogenMip Assay is a widely accessible protocol for producing and using highly
discriminating probes, with experimentally validated results in pathogen genotyping, which could potentially be applied to
the detection and characterization of any microbe.
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INTRODUCTION
Multiplex assays to identify the presence of a wide variety of
microbes within a specimen will have a profound impact on the
efficient management of disease treatments and prevention,
clinical follow-up studies, and the development of new therapies
of prophylactic or therapeutic vaccines. Here we describe
a complete protocol for a multiplex assay in single-tube reactions
useful in pathogen diagnostics. We compare our results to those
obtained from a conventional general-primer based amplification
[1] approach when genotyping primary tumor genomic DNA
extracts from cervical cancers.
Nucleic-acid based diagnostic techniques typically rely on
unbiased PCR amplification [2] of the targets, which requires
a set of general PCR amplification primers to hybridize upstream
and downstream of the variable region, followed by either real-
time PCR [3], hybridization assays [4] or template sequencing [5]
for read-out interpretation. Multiplex PCR [6], has the potential
to decrease cost, time and effort in pathogen diagnostics [7].
Engineering an efficient multiplex PCR requires laborious
strategic planning in primer design, nucleotide concentrations,
optimal salt and buffer conditions, and use of chemical adjuvants
[8] and is rarely capable of achieving multiplex degrees greater
than a 20-plex.
The field of molecular diagnostics is experiencing a revolution
in regards to theranostics, the integration of diagnostic technol-
ogies with therapeutic applications [9]. As the number of
biomarkers for microbial agents and disease markers [10]
increases, simultaneous detection of multiple agents or risk factors
implicated in particular clinical syndromes or diseases that share
similar epidemiological features will become highly desirable.
Groundbreaking research has been performed with the advent of
a ligase-mediated gene detection technique [11] and the many
technologies based on the work of Landegren et al [12]. Ligase-
based technology has led to myriad promising techniques such as
the padlock probe [13,14], and the proximity ligation assay [15],
which have both been investigated as potential pathogen di-
agnostic methods [15,16]. Molecular Inversion Probe (MIP)
technology [17], has contributed new features to padlock probes,
resulting in an ultra high-throughput method for SNP detection
[18] and further investigation as a potential quantitative method
[19].
As a model assay for MIP pathogen diagnostics, we chose to
target the Human Papillomavirus (HPV), which is well known for
its cancer-associated cervical infections and for the existence of
multiple genotypes [20]. Based on the oncogenic potential, the
subtypes are classified as ‘‘high-risk’’ or ‘‘low-risk’’ HPVs. We
developed a 24-plex PathogenMip assay to target HPV genotypes
commonly associated with cervical cancer progressions [21]. The
MIP assay was performed in four sequential enzymatic driven
reactions (Figure 1). Target recognition sites for the MIPs in this
assay were designed using a previously described software tool,
PathogenMIPer [22]. We also attempted to introduce a novel
ligase-dependent probe production at equal or increased assay
effectiveness, which would be less expensive than direct manufac-
ture of full-length probes. Pyrosequencing [23] and hybridization
[24] were applied to the HPV amplified L1-region to validate the
results obtained from the PathogenMip Assay.
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Ligation-based probe construction
For cost-efficient production of MIPs, two shorter DNA constructs
(denoted A and B) were produced in-house and ligated through
a ligation-based production assay (Figure 2). Several different assay
protocols wereexamined, inwhich: i) dCTP,dTTPand apolymerase
(Stoffel fragment) were added to the ligation reaction, ii) bridge
concentrations werevaried from ratiosof 2:1 down to 1:4 withrespect
to the concentrations of the A and B constructs, and iii) Ampligase
was replaced with a T4 DNA ligase based kit (Fast-Link DNA-
ligation kit, Epicenter Biotechnologies; Madison, WI). Gel-electro-
phoresis was used as read-out for all optimizations (data not shown).
Thus, best results with regards to yield and purity were achieved
by inclusion of Stoffel fragment, dCTP and dTTP, and use of
equal concentrations of bridge, A, and B constructs. No noticeable
differences were seen with the use of different ligase-enzymes, and
Ampligase was used in subsequent tests. Using this protocol, the
ligation step produced clear DNA gel-bands at a 100 base pairs,
which were isolated and purified. All 25 probes (including the
reference probe, rMIP, which targets the b-globin region in human
DNA) were pooled together into a mixture of roughly equal probe
concentrations with a total concentration of 5 fmol/probe.
PathogenMip Assay validation
Our primary goal was to specifically genotype each target while
using a complete 25-plex MIP mixture (24 HPV probes plus the
control rMIP), without generation of false-positives or negatives.
To enhance sensitivity and selectivity, we explored a variety of
initial probe concentrations and thermoprofiles for the initial
ligation and gap-filling step (Figure 1B). All optimizations of the
PathogenMip Assay were based on UV-visualization of DNA band
intensities after size separation by gel electrophoresis (data not
shown). The initial probe concentrations yielded an appropriate
signal when using 5 fmol of each contributing probe. Cycle times
Figure 1. Schematic overviews of molecular inversion probe technology. A) Synthetic oligonucleotide containing following four regions; i) H1 and H2:
homology regions comprised of unique continuous 40–50 base pair fragments for target recognition ii) BARCODE: molecular barcode comprised of
a 20 base pair DNA tag for target identification iii) U1 and U2: universal primer regions for inverted probe amplification, and iv) R: restriction site for
probe linearization. B) Upon target recognition, a DNA polymerase fills the missing gap in between the juxtaposition of the probes’ flanking ends,
and through the activity of a DNA ligase the probe is circularized. In all cases the missing nucleotide is a ‘‘G’’. C) Circular DNA enrichment through
DNA degradation by enzymes Exonuclease I and III. D) Probe linearization restriction site cleavage. E) All reacted and inverted probes are amplified
with universal primers, of which one is biotinylated for subsequent amplicon validation.
doi:10.1371/journal.pone.0000223.g001
Figure 2. Ligase-based probe construction for the PathogenMip Assay. Seen in the figure is the sequence for probe-16 prior to inversion. Two shorter
fragments were synthesized and hybridized to a bridge complementary to the universal primer regions, common for all probes used in the assay. The
coupling of the shorter fragments was mediated by polymerase and ligase activity to achieve maximum yield.
doi:10.1371/journal.pone.0000223.g002
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efficient protocol, comprising 5 cycles of denaturing and two
annealing times at 50uC and 37uC.
Using the optimized conditions, all 21 HPV plasmids and 3
oligonucleotide targets (see Materials and Methods, DNA materials)
were detected with the PathogenMip Assay, and sequencing
individually validated each result. The positive control, rMIP, was
successfully validated through a reaction with a commercially
available human genomic DNA, without positive matches to any
of the HPV genotypes.
PathogenMip Assay performance
To further investigate assay sensitivity, we used a fixed concen-
tration of the MIP mixture at 5 fmol/probe in the ligation step,
while varying the amount of target DNA. This experiment was
performed in two versions. The first set of reactions contained
pure plasmids. The second set of reactions contained, in addition
to the target plasmids, a constant amount (200 ng) of non-reactive,
commercially available human genomic DNA. By spiking with
human genomic DNA we hoped to approximate more realistic
sample environments for which the assay was constructed. So that
the experiments would be of significant value, the probe mixture
did not include the rMIP, since rMIP would react with the human
genomic DNA and give false quantification data. The plasmid
concentrations ranged from 100 ng to 10 fg through a 10-fold
dilution series. The original detection limit goal for the assays was
1 pg in the pure plasmid environment and 1 ng for plasmid in the
presence of 200 ng human genomic DNA (data not shown), when
cycling the PCR reaction at 35 cycles. By using an alternative PCR
protocol, working at a higher annealing temperature (58uC) for 60
cycles, we were able to improve the sensitivity of the assay. No
background was observed with either of the PCR conditions, but
a 10-fold higher sensitivity was obtained with the more extensive
60 cycle-protocol. The new detection limit values were 100 fg for
the pure plasmid and 100 pg for plasmid in the presence of 200 ng
human genomic DNA (data not shown). Targets in all reactions
were correctly typed as judged by L1-pyrosequencing validation.
In multiple HPV-infections, the viral load of each contributing
genotype can differ by orders of magnitude [5]. To obtain a deeper
understanding of the assay’s capabilities when faced with such
challenges, we set up a series of reactions to mimic this possibility.
Here we chose a two-plasmid detection model in which plasmid
HPV-45 was present at a fixed amount of 100 ng, while the second
plasmid HPV-59 was present in a wide concentration range. In
this scenario, we were able to obtain interpretable data for both
genotypes for up to 2-logs difference in target DNA concentration,
using the PathogenMip Assay on the different in parallel with
pyrosequencing to confirmresults (Figure 3).
Genotyping of primary tumor genomic DNA extracts
The ultimate objective was to screen samples with unknown viral
load. A total of 20 commercially available primary tumor genomic
DNA extracts were collected from patients with cervical cancers.
The DNA samples were screened through the HPV PathogenMip
Assay and detected using both methods (pyrosequencing and the
in-house barcode-chip assay). The results were validated by
genotyping the samples in parallel using the conventional general
primer based nested PGMY09/11 and GP5+/6+ amplification
protocol. For all tumor-drived samples, the agreement among the
methods (PathogenMip Assay and conventional genotyping) was
100%, with 10 samples positive for HPV-16, 5 for HPV-18, two
for HPV-45, two for HPV-59 and one sample returning as HPV-
negative. When using 200 ng of genomic DNA extract for the
PathogenMip assay, equal levels of detection efficiency were
obtained for both methods (Figure 4).
Multiplexing capabilities
We also performed the PathogenMip assay screening a mixture of
multiple HPV plasmids set at equal concentrations of a 100 ng.
Many patients have multiple HPV infections and, though rare,
such patients are known to carry as many as five subtypes [5], so
we set as our goal to prove that it is feasible to detect four
simultaneous infections at equal viral loads using the PathogenMip
Assay. HPV plasmids of four high-risk HPV genotypes (-16, -18, -
34, and -59) were pooled in equal amounts at a 100 ng/plasmid,
and screened simultaneously in triplicate using the complete 25-
plex-probe mixture. The reactions were then validated by both
pyrosequencing and hybridizations methods. All four HPV
subtypes were detected at similar detection intensities differing
by 620% from the median value, when hybridized through the
barcode to an in-house barcode-chip (Figure 5).
DISCUSSION
A complete pathogen detection assay based on MIP technology is
under construction. Here, we describe a successful model assay
targeting 24 HPV genotypes most commonly associated with the
progression to cervical cancer. Our pilot subset can now be
extended to include all known sequenced HPV genotypes, as
multiplexing up to 20,000 using the MIP method for human SNP
genotyping, has been demonstrate to be feasible (www.affymetrix.
com/technology/mip_technology.affx), and this would more than
cover the existing variability in the HPV genome.
In the case of a double HPV infection, the fact that the
PathogenMip Assay detected and distinguished between two
contributing viral loads that differed by 2-logs at an input level of
200ng genomic DNA is quite promising. While DNA yields from
tumors vary widely, this level is in the mid-range of recovery in our
experience. Exploration of a more full matrix of DNA double-
loads and inputs is under way.
Primary tumor genomic DNA extracts were efficiently geno-
typed for a wide dynamic range of viral loads (Figure 4). The
reference probe (rMIP) provided a positive reference control in
each performed reaction (Figure 4) and, if used to normalize viral
loads against total human genomic DNA content, may allow the
researcher a tool to compare viral loads from genomic DNA
extracts. The results of the PathogenMip Assay genotyping were in
100% agreement with the conventional genotyping methods.
Our goal was to provide a complete, experimentally validated
assay in a ready-to-use format, which could be applied generically
to any pathogen based on genome target recognition. Pathogen-
Miper [22] serves as an in silico multiplex test system, whereby one
can check the feasibility of designing a MIP assay for the specific
targets one might want to include in a multiplex detection assay.
Microbial genomes commonly incur variations from insertions,
deletions, or mutations that can generate false-negative results if
the variation resides within a probes’ targeted region. A more
complete diagnostic approach would be to include multiple probes
per genotype; this would also provide deeper epidemiological
insights in functional genome patterns and variations, i.e.
mutations coding for drug resistance [25]. Conventional PCR-
based genotyping methods are restricted to reside within
conserved genomic regions, which limits the choice of genotyping
targets [1,26]. These methods are not robust to genomic changes,
a problem that can be at least partially addressed by the
multiplexing possible in the PathogenMip Assay.
Pathogen Detection Assay
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a ligation step to facilitate probe generation. An oligonucleotide
complementary to the universal primer region, which is present in
each probe, can be used as a bridge so that one longer probe can be
ligated together from two smaller constructs, and length require-
ments for probe synthesis are therefore cut in half. Longer
oligonucleotides result in higher initial costs, and have been known
to compromise sequence quality [27]. With our new ligation-based
probeproduction,we introducecost-efficient probeproductionwith
possibilitiesforinnovationandpotentialincreaseinefficiency.Probe
productionusingtheligationmethod caneasilybeperformed inany
academicorother researchinstitution withbudget constraints,using
only standard labware and avoiding core facility based research. We
are currently investigating parameters for increased ligation
efficiency and probe production. The goal of such efforts would
be a more homogeneous distribution of probe concentrations, thus
enabling one to perform high-throughput production via one-tube
reactions and use of fully automated workstations, e.g. Biomek FX
(Beckman Coulter, Palo Alto, CA). Parameters that could be varied
to this end include ligation at higher temperatures (preferred 65uC)
to allow improved incubation profiles, and higher cycle numbers
[28]. Use of modified nucleotides, e.g. locked nucleic acids (LNA)
[29] in the bridge would allow for higher melting temperatures (Tm)
for the universal primer regions. Also by replacing the conventional
gel-purification protocol with one based on single-strand DNA
separation, higher purity of ligated versus non-ligated DNA can be
achieved, resulting in a more sensitive assay (data not shown). The
introduction of a second universal primer region would require
a ligation-based production assay based on three contributing
constructs and two bridges complementary to the two universal
primer regions. By designing the new probes so that the two primer
regions flank the barcode region, a three-way ligation currently
under investigation would result in new design features regarding
assay possibilities and efficiency.
Although our preferred readout for the PathogenMip Assay uses
sequencing or hybridization of the identifying barcode, we also
used sequencing of the target-homologous regions of the
PathogenMip inverted probes to double check target identity. In
addition, we performed conventional HPV identification through
the sequencing of the L1 regions. All three assays (PathogenMip/
barcode, PathogenMip/target region, and HPV L1 sequencing)
produced the same final result with respect to target identification,
Figure 3. Probe selectivity. The figure depicts superimposed pyrosequencing (dispensation time vs. light signal intensity) diagrams for two probes
following the MIP reactions, targeting HPV-45 (black) and HPV-59 (red), mimicking a double HPV infection. A) The initial DNA amount of each
contributing plasmid was 100 ng and equal levels of sequencing intensities are seen. B) The DNA amount of HPV-45 plasmid remained at 100 ng,
while HPV-59 plasmid was set at 10 ng resulting in ,2-fold lower signal intensity. C) DNA amounts were set at 100 ng for HPV-45 plasmid and 1
nanogram for HPV-59 plasmid, which was observed as a ,3-fold decrease in signal intensity. D) DNA amounts of 100 ng of HPV-45 plasmid and
100 pg of HPV-59 plasmid resulted in signal from HPV-45-probe without a measurable signal from the probe for HPV-59.
doi:10.1371/journal.pone.0000223.g003
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cing or hybridization methods. Pyrosequencing of the ID-tag was
more time and cost-efficient than either hybridization to the in-
house barcode-chip or the L1-hybridization-assay. Multiple-
primer pyrosequencing, however, is limited to reactions of 20-
plex or lower. A higher degree of multiplexing in a sequencing-
based approach might be achieved through use of a high-
throughput configuration of the pyrosequencing method; for
example, the one offered by 454 Life Sciences (http://www.454.
com/applications/index.asp). However, when high capacity is
required, hybridization-based methods show more potential than
sequencing methods, and here the PathogenMip Assay has the
advantage of providing more discrimination through its targeted
probes than would a standard hybridization to highly conserved
regions. The use of ID-tag markers incorporated in the probes
simplified sequence read-out in the current PathogenMip Assay,
but a more forward looking approach involves refinement of the
in-house barcode-chip hybridization piloted here. We anticipate
that a high-throughput configuration of the current PathogenMip
assay will be achievable through use of the commercially available
Affymetrix TAG4-array [30], which is based on detection of
barcodes through hybridization similar to the process described
here. The TAG4-array covers a total of 80K features, which
includes a total of 16,000 unique barcodes in five replicates.
Sensitivity levels obtained with the current assay were sufficient
for a functional assay and were improved with the use of a more
extensive amplification protocol. Previously described ligation-
based genotyping methods [16,31] have shown sensitivity ranging
down to nanograms of genomic DNA for accurate genotyping.
These methods have placed careful emphasis on the amplification
step by either rolling circle amplification method [32] or stringent
reaction cleanup with reversible magnetic biotin-streptavidin
separation [33], followed by design of a PCR run at high
annealing temperatures and high cycle numbers, which also could
be performed with the use of LNA universal primers [34]. Further
consideration of these parameters should allow improvement in
sensitivity of a next-generation PathogenMip Assay.
The potential uses for an assay that simultaneously detects
multiple organisms based on differences in DNA sequences are
almost unlimited. MIP-based diagnostics have already progressed
in the field of human SNP-detection and cancer diagnostics [10]
with ongoing clinical trials. Microarray techniques have gained
ground in the pathogen diagnostic arena, with various genotyping
chips such as the HPV-assay PapilloCheck (www.greinerbioone.
com) upcoming. By combining the benefits of a high-throughput
multiplex MIP-assay prior to PCR amplification and of a post-
PCR hybridization based chip read-out, researchers can expand
the scope of their surveillance to reach new insights into
Figure 4. Bar-histograms representing fluorescence intensities from the in-house barcode-chip for genotyping genomic DNA extracts from tumor
samples derived from four patients with cervical cancers. Seen in the figure are four examples of single HPV infections, one from each genotype,
observed in the sample set. HPV-16 was genotyped in sample OM-1751, HPV-18 in OM-1452, HPV-45 in OM-2258 and HPV-59 in OM-1569. The signal-
intensities were normalized to the intensity of the peak for the reference probe targeting human b-globin gene (rMIP). The remaining bars constitute
of the reaction background signal.
doi:10.1371/journal.pone.0000223.g004
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researchers with expertise in various pathogenic microbes to adapt
the PathogenMip Assay to accomplish similar detection screenings
as performed in this study. By combining the different models, we
can reach a common goal toward a standardized virus-, bacteria-,
or fungi- chip for routine diagnostics and epidemiological studies.
MATERIALS AND METHODS
Experimental design
Our goal was to design an assay to simultaneously distinguishing
among over 100 HPV genotypes that differ only slightly in their
genomic sequences (up to 90% homology). The critical regions of
the probes that recognize and distinguish among the HPV
subtypes were generated using PathogenMIPer, a previously
described software tool [22]. Each target sequence was designed
through multiple, successive steps of evaluation of candidate
sequences, based on user-defined criteria, followed by a BLAST
search against non-target genomes potentially present in the
sample that could otherwise cause background noise or interfere
with signal. For the study, we included 24 HPV genotypes (Table 1
and Figure 6A) most commonly associated with cervical cancer
progression [20]. Our design strategy allowed the probes to target
any region of the approximately 8000 bp viral genome. Probes
that targeted the E6/E7 genes were preferred, since these genes
are most commonly associated with cervical cancer progression
[35]. The HPV-PathogenMip Assay also included a reference
probe (rMIP) targeting the b-globin region in human DNA
(Table 1). Validation was performed by either ID-tag based
multiple-primer DNA sequencing [5] or barcode hybridization,
Figure 5. Results from the in-house barcode-chip screening of a quadruple HPV-infection. A) In-house barcode-chip at wavelength 635 emitting the
fluorophore signal for internal control Linker A, positive for all oligonucleotides in the chip. B) Wavelength 535 emitting the fluorophore signal for the
biotinylated MIP amplicons and the positive control. The in-house barcode-chip was positive for all four HPV genotypes in the pool (HPV-16, -18, -34
and -59). C) Wavelength ratio 535/635 representing the signal ratio from the positive samples to that from linker A. D) Bar histograms representing
mean value signal intensities for 2 arrays analyzed with 5 replicates per chip. The highest peak signal for HPV-59 was used for normalization for all the
values in the graph for visual purposes. The variability in probes intensities can be explained by individual differences in probe composition and
a batch-to-batch variation in the production of the probes.
doi:10.1371/journal.pone.0000223.g005
Pathogen Detection Assay
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chip. Each ID-tag was carefully designed so that it was easily
distinguishable when up to four probes were sequenced in parallel
during the validation reaction, without primer cross hybridization
(Table 2 and Figure 6B). A conventional genotyping assay was run
in parallel, based on nested PCR amplification (Figure 6C). The
PCR amplicons were followed by sequencing or hybridization
interpretation (Figure 6D–E).
DNA materials
All oligonucleotides used in the assay (Table 3) were produced in-
house (Stanford Genome Technology Center). HPV plasmids
were kindly provided by Dr. E. M. de Villiers (DKFZ; Heidelberg,
Germany) (HPV-6, 11, 16, 18, 40, 45, 51 and 73); HPV-33, 34,
39, 42 and 66 by Dr. M. Favre (Institute Pasteur; Paris, France);
HPV-31, 35, 43, 44, and 56 by Dr. A. Lorincz (Digene
Corporation; Gaithersburg, MD); HPV-59 and 82 DNA by Dr.
T. Matsukura (National Institute of Health; Tokyo, Japan) and
HPV-52 by Dr. W. Lancaster (Wayne State University School of
Medicine; Detroit, MI). The HPV plasmids were normalized at
100-ng/ml using a ND-100 Spectrophotometer (NanoDrop,
Wilmington, DE). Because we lacked plasmids containing HPV
subtypes 58, 68, and 69, we manufactured synthetic oligonucle-
otide targets, denoted as TEMP-58, -68 and -69 to complement
the homologous regions of our probes for these genotypes
(Table 3B). Twenty commercially available primary tumor
genomic DNA extracts were obtained from Oncomatrix, Inc.
(www.oncomatrix.com). Commercially available human genomic
DNA G3041 (Promega, Madison, WI) was also used for assay
validation.
Ligation-based probe construction
The full-length probes were designed to be of ,110 base pairs.
Each probe was synthetically manufactured in two shorter
fragments, A and B, at about 50 base pair lengths, and with 59-
phosphorylated modifications (Table 3A). HPV-complementary
portions of the probes were designed using PathogenMIPer,
a previously described software tool for designing unique and
specific probes, targeting any type of genome based on its
sequence data in a FASTA file format [22]. The universal primer
region was chosen for the point of the A and B fragment
separation, 10 base pairs upstream (59-39 directional viewpoint) of
the first dUTP residue. A complementary bridge oligonucleotide
was designed (Table 3B) to hybridize to the universal primer
region. Ligation was performed in a one-step reaction. Equal
concentrations (2.5 mM) of construct A, construct B, and the
bridge oligonucleotide were pooled together with 2.5 units of
Ampligase (Epicenter Biotechnologies, Madison, WI), 5 units of
AmpliTaq DNA Polymerase Stoffel Fragment (Applied Biosys-
tems, Foster City, CA) and 1.25 mM of each nucleotide dCTP
and dTTP (Fermentas, Hanover, MD). A GeneAmp PCR system
9700 (Applied Biosystems, Foster City, CA) thermocycler was used
for initial heating at 95uC for 10 min, followed by 5 cycles of
denaturation and hybridization/ligation at 95uC for 2 min and
50uC for 2 min. The ligation products were then run out on a Sub-
Cell GT Agarose Electrophoresis System (Bio-Rad, Hercules, CA)
using a 2.5% Ultra pure L.M.P Agarose gel (Invitrogen, Carlsbad,
CA) with 5 mg/ml Ethidium Bromide (Sigma-Aldrich, St. Louis
MO) staining. Gel bands of fragments at about a 100 bases were
carefully cut out and dissolved in 0.4 M NaCl at 70uC. DNA
extraction of the gel bands was based on a phenol and chloroform
(Sigma-Aldrich, St. Louis, MO) organic extraction protocol. The
aqueous phase was collected after organic phase separation with
equal volumes of: i) phenol, ii) 1:1 phenol/chloroform, and iii)
chloroform. This procedure was followed by ethanol precipitation
at 220uC over night. Glycogen (Sigma-Aldrich, St. Louis, MO)
was added to facilitate DNA precipitation. The purified probes
were normalized for probe concentration using a ND-100
Spectrophotometer (NanoDrop, Wilmington, DE).
PathogenMip Assay
Prior to the assay, genomic DNA was fragmented by digestion
with EcoRI and Xba I according to manufacturer’s instructions
(New England BioLabs; Ipswich, MA). MIP reactions were
performed as follows: i) 200 ng of previously digested genomic
DNA (or 50 ng undigested HPV plasmid DNA), 5 fmol each of 25
probes, 0.25 units of (Epicenter Biotechnologies, Madison, WI),
0.25 mM dGTP (Fermentas, Hanover, MD), and 1 units of
AmpliTaq DNA Polymerase Stoffel Fragment (Applied Biosys-
tems, Foster City, CA) in 16 Ampligase buffer (Epicenter
Biotechnologies, Madison, WI) run in a total volume of 10 ml/
rxn. After pre-incubation at 95uC for 10 min, the reaction went
through 5 cycles of 95uC for 2 min, 50uC for 30 min and 37uC for
10 min. ii) 10 ml of 130 mM Tris-HCl (pH 7.8), 85.75 mM KCl,
3.85 mM MgCl2 and 0.1% BSA solution containing 5.6 units
Exonuclease I and 112 units Exonuclease III (Epicenter Bio-
technologies, Madison, WI) was added to each reaction. The
Table 1. Probes used in this version of the PathogenMip
Assay.
......................................................................
Probe HPV genotype Cancer risk group Accession number Gene
rMIP - - AY310318 HBB
6b HPV 6b Low-risk X00203 E1
11 HPV 11 Low-risk M14119 E5
16 HPV 16 High-risk K02718 E6
18 HPV 18 High-risk X05015 L1
31 HPV 31 High-risk J04353 E1
33 HPV 33 High-risk M12732 L2
34 HPV 34 High-risk X74476 E7
35 HPV 35 High-risk M74117 E1
39 HPV 39 High-risk M38185 E6
40 HPV 40 Unspecified X74478 L2
42 HPV 42 Low-risk M73236 E7
43 HPV 43 Low-risk NC_005349 L2
44 HPV 44 Low-risk U31788 L1
45 HPV 45 High-risk X74479 E1
51 HPV 51 High-risk M62877 L2
52 HPV 52 High-risk X74481 E7
56 HPV 56 High-risk X74483 E6
58 HPV 58 High-risk D90400 L2
59 HPV 59 High-risk X77858 E7
66 HPV 66 High-risk U31794 L1
68 HPV 68 High-risk NC_004710 E6
69 HPV 69 Unspecified M73258 E7
73 HPV 73 Unspecified U21941 E6
82 HPV 82 Unspecified X94165 L2
For each probe, information is provided regarding which HPV genotype (or
human gene) it targets, NCBI accession numbers, and the genes where the
recognition sites lie.
doi:10.1371/journal.pone.0000223.t001
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PLoS ONE | www.plosone.org 7 February 2007 | Issue 2 | e223mixture was incubated at 37uC for 60 min followed by enzyme
deactivation at 80uC for 20 min. iii) 4 units of Uracil-DNA-
Glycosylase (New England BioLabs, Ipswich, MA) was added to
each reaction and incubated at 37uC for 20 min followed by
enzyme deactivation at 80uC for 20 min. iv) PCR amplification
was carried in a total reaction volume of 50 ml, containing 5 ml
MIP reaction, GeneAmp 1X PCR Buffer II (Applied Biosystems,
Foster City, CA), 2.5 mM MgCl2 (Applied Biosystems, Foster
City, CA), 0.12 mM dNTPs (Fermentas, Hanover, MD), 2.5 units
AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster
City, CA) and 0.2 mM of each universal primer B-F-CHPV-U1
and R-CHPV-U2 (Table 3B). A 10-min incubation step at 95uC
was followed by 35 cycles of amplification with a thermocycler
GeneAmp PCR system 9700 (Applied Biosystems, Foster City,
CA). Each cycle included a denaturation step at 95uC for 45 sec,
and an annealing step at 52uC for 30 sec. A final extension was
done at 72uC for 5 min. For three randomly chosen reactions, an
alternative PCR protocol was run in parallel, which was comprised
of 60 cycles with an increased annealing temperature at 58uC. The
Figure 6. Schematic overview of the PathogenMip Assay. A) The 24 probes included in the assay are situated at their respective target sites on the
approximately 8000 base pairs of double stranded HPV genomic DNA. Early genes (denoted E) code for virus integration and replication and late
genes (denoted L) encode the viral capsule creation. The probes recognize ,40 base pair fragments unique for each targeted genotype. B) Following
enzymatic inversion of reacted probes and universal amplification, the amplicons are used for subsequent appropriate HPV genotype screening. C)
Conventional HPV genotyping takes a different approach, in which the nested primer pairs PGMY09/11 and GP5+/6+ amplify respectively ,450 base
pair and ,150 base pair fragments that, through an appropriate readout process, will make up the basis for genotyping. These primers are restricted
to the highly conserved genomic regions, most commonly found in the L1 gene. D) Multiple-primer DNA Pyrosequencing of an incorporated ID-tag.
The diagrams depict the complementary sequence of the investigated probes -16 and -18. Marked in the figure is the ID-tag for each probe and the
point of ligation where the probes circularized, incorporation of a dGTP, seen here as the complementary ‘‘C’’. E) The in-house barcode chips here
used to detect one HPV-16 positive, and one HPV-18 positive in human genomic DNA presence as seen with a positive rMIP in both chips.
doi:10.1371/journal.pone.0000223.g006
Table 2. ID-tags and multiple-primer mixes of complementary
barcode sequencing primers (cBarcodeS) for effective DNA
sequencing readout.
......................................................................
ID-tags
Multiple
Primer Pool CCAT TTAT GGAC GGACCT
Mix 1 cBarcodeS-16 cBarcodeS-68 cBarcodeS-35 cBarcodeS-51
Mix 2 cBarcodeS-31 cBarcodeS-11 cBarcodeS-59 cBarcodeS-56
Mix 3 cBarcodeS-45 cBarcodeS-52 cBarcodeS-39 cBarcodeS-58
Mix 4 cBarcodeS-66 cBarcodeS-18 cBarcodeS-69 cBarcodeS-34
Mix 5 cBarcodeS-6 cBarcodeS-33 cBarcodeS-42 cBarcodeS-82
Mix 6 cBarcodeS-40 cBarcodeS-43 cBarcodeS-73 cBarcodeS-44
cBarcodeS-rMIP CAGGG
For verification purposes, the first 5 bases for the rMIP obtained from 2 cyclic
(ACGT) dispensations are also included.
doi:10.1371/journal.pone.0000223.t002
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assay could be achieved with a more extensive PCR amplification.
Multiple-primer DNA pyrosequencing of barcodes
The B-F-CHPV-U1 primer used for universal probe amplification
was biotinylated, and the leading strand could therefore be used as
a sequencing template. Single strand template preparation was
performed as previously described [23], and oligonucleotides
complementary to barcodes included in the probes were used as
sequencing primers (Table 3B). Each of the 24 HPV targeting
probes contained one out of four ID-tags, which lay the basis for
a rapid multiple-primer based screening by sequencing [5]. The
primers were pooled into six mixes of four primers with different
ID-tags (Table 2). Pyrosequencing was performed with a cyclic de
novo sequencing dispensation (ACGT) using a PSQ
TMHS96A
DNA sequencing system.
Microarray barcode-chip template preparation
For more efficient microarray hybridizations, single stranded DNA
was generated from the first PCR amplification. Amplification was
carried out in a total reaction volume of 50 ml, containing 1 ml
from the first PCR reaction, 0.1256 BD Titanium Taq DNA
polymerase (Clontech, Mountain View, CA), 1X BD Titanium
Taq PCR buffer (Clontech, Mountain View, CA), 0.2 mM dNTPs
(Fermentas, Hanover, MD) and 0.2 mM of each universal primer
B-F-CHPV-U1. A 10 min incubation step at 95uC was followed
by 35 cycles of amplification with a thermocycler GeneAmp PCR
system 9700 (Applied Biosystems, Foster City, CA). Each cycle
included a denaturation step at 95uC for 45 sec, and annealing at
54uC for 30 sec. A final extension was performed at 68uC for
5 min.
Barcode microarray preparation
Oligonucleotides were synthesized at the Stanford Genome
Technology Center. Oligonucleotides used as probes on the array
(Table 3B) consisted of (from 59 to 39): a 59-amino group (for
attachment to the array), a 5 bp poly-T sequence, Linker A, and
a 20 bp complementary to barcode sequence. Probes were
attached to the microarray essentially as described previously
[24]. Each probe was printed in quadruplicate or quintuple, and
two complete arrays were present on each chip. The post-printing
processing of the microarrays was performed as recommended by
the slide manufacturer (Amersham Biosciences, Piscataway, NJ).
Control oligonucleotides used to verify array quality included
a poly-T (20 bp) with 59-amino and internal-biotin modification as
a labeling control (amino-B), a oligonucleotide complementary to
Linker A with internal-Cy3 (amino-P) as an internal control for
each spot’s quality, and a 59-amino modified poly-T (20 bp) as
a DNA spacer.
Array hybridizations
In the hybridization step, the biotinylated single-stranded target
and amino-P were applied to the microarray. For the initial target
hybridization step, we used 50 ml of target DNA in 16
hybridization buffer (100 mM MES, 1 M [Na+], 20 mM EDTA,
0.01 Tween20), 1.256 Denhardt’s solution, and 5 nM amino-P.
The hybridization was performed at 42uC for 12–16 hours. After
hybridization, the microarray was washed 3 times in wash buffer
and then labeled for 10 min at 50uC with a solution containing
streptavidin-allophycocyanin (1mg/ml final concentration), 66
SSPE, 16 Denhardt’s solution, and 0.01% Tween-20. The
microarray was scanned for fluorescence intensity at 535 nm
and 635 nm using a GenePix 4000 fluorescent scanner (Axon
Instrument, Foster City, CA) set to scan at 450 PMT. GenePix Pro
software was used to determine the total fluorescence signal from
each spot on the array.
Validation and genotyping of DNA samples
For validation of the PathogenMip Assay, the 20 genomic DNA
extracts were characterized for HPV presence and subtypes with
nested PCR amplification using general primers PGMY09/11 and
GP5+/6+ [1] according to a previously described protocol [26]
with an initial amount of 40 ng/ml genomic DNA, followed by
sequencing as described previously [5].
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